Eli Lilly and Company is making another big addition to its manufacturing and research and development capacity with a plant close to its Indianapolis headquarters that is set to open in a few years. The announcement closely follows the opening of a plant in the same area that Lilly is using to ramp up capacity to meet rapidly burgeoning demand for its diabetes and obesity products.
Lilly Makes Another Big Investment In Manufacturing Capacity
The drug maker will spend $4.5bn on a “Lilly Medicine Foundry” that it said would provide extra manufacturing capacity as well as research ways to improve manufacturing processes.
More from Manufacturing
• By
J&J followed in the footsteps of Lilly and Merck, which have announced multibillion-dollar investments in US manufacturing since Donald Trump’s inauguration.
• By
A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.
• By
Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.
• By
Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.